Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium

Br J Ophthalmol. 1995 May;79(5):439-41. doi: 10.1136/bjo.79.5.439.

Abstract

Aims: A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted.

Methods: A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months).

Results: Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group.

Conclusion: Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Combined Modality Therapy
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Intraoperative Care*
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use*
  • Prospective Studies
  • Pterygium / drug therapy
  • Pterygium / prevention & control
  • Pterygium / surgery*
  • Recurrence

Substances

  • Mitomycin